Key-Drugs-Mnemonics-Study-Tips-Pebc-Osce-Resources.pdf

RXPREP:
KEYDRUGS,
MNEMONI
CS,
STUDY CYPi nhibitors
o G<3PACMAN( bi gi nhi bitors)
TI
PS  Gr apef rui t
 HAZARDOUSDRUGSar e:  PI spr ot easei nhi bitor s(ritonav ir
)
o Ter at ogeni c  Azol eant i
f ungal s( fluconazol e,
o Car ci nogeni c itraconazol e, ket oconazol e,
o Genot oxi c( damaget heDNAandcancause posaconazol e, vor i
conazol e,
cancer ) isav uconazoni um)
o Hav er epr oduct i
v et oxi ci ty  C: CYA, cimet idine, cobi cist at
o Causeor gant oxi cityatl owdoses  Macr ol i
des( clarithromy cin,
 Keyhazardousdr ugst hatr equi reSPECI AL er y thromy cin, notazi thromy cin)
HANDLINGt oav oidt oxi ci t
yt owor ker s:  Ami odar one( anddr onedar one)
o Al l pregnancycat egor yXdr ugs, cat egor yD’ s  Non- DHPCCBs( dilti
azem and
andaf ewC’ s, andpar oxet ine, met hotrexat e, v er apami l
)
mi sopr ost ol, mi fepr istone, r i
bav ir
in  KeySEROTONERGI Cdr ugs:
o Ant ineopl ast ics( chemot her apeut i
cs) o SSRI s
o 5- alphar educt asei nhi bi tor s( dut asteride, o SNRI s
fi
nast er ide) o TCAs
o Hor mones( cont racept iv es, estr adiol, o MAOI s( plusl i
nezol idandmet hy l
enebl ue)
test ost er one) o Buspi rone
o Tr anspl antdr ugs( MMF, tacr oli
mus, CYA, o Dext romet hor phan
ever ol imus, sir olimus) o Fent any l
o Ot her s: col chi ci ne, dr onedar one, fl
uconazol e, o Li thium
spir onol act one, ri
sper idone, raloxi fene, o Met hadone
rasagi li
ne, zi pr asidone o Mi rtazapi ne
 Keydrugsmostcommonl yassoci at edwi t
h o St .John’ sWor t
PHOTOSENSI TI VITY: o Tr amadol
o Car bamazepi ne o Tr azodone
o Di ur et i
cs( thiazi deandl oop) o Ot her s:cy clobenzapr ine, lorcaser i
n,
o MTX meper i
di ne, 5HT3- RA, somet riptans
o Or al andt opi cal retinoi ds  Keydr ugsr equi red/ strongl yr ecommendedPGx
o Qui nol ones test
ing:
o St .John’ sWor t o Abacav ir
o Sul faant i
bi ot ics o Azat hiopr ine
o Tacr olimus o Car bamazepi ne
o Vor iconazol e o Cet uxi mabandpani tumumab
o Ot her s: ami odar one, ant ihi stami nes( 1st o Tr ast uzumab, ado- transt uzumab, lapat ini
b,
gener at i
on) , chl or oqui ne, coal tar, pertuzumab
fl
uor our aci l, gr i
seof ulv i
n, NSAI Ds, quini dine, o Ot her s:al lopur inol ,capeci tabi ne, f
luor ouraci
l,
ti
gecy cline cl
opi dogr el, codei ne, pheny toi n, f
ospheny toi
n,
 Keydrugscommonl yassoci atedwi thTTP: warfar in
o Cl opi dogr el  Keydr ugs-DONOTputt hesedr ugsi ntoPVCI V
o Ti clopi dine CONTAI NERS
o Ot her s: acy clov i
r ,famci cl ov ir,qui nine, SMX, o LATI N
valacy clov ir  Lor azepam
 CYPinducer s  Ami odar one
o PSPORCS( bigi nducer s)  Tacr olimus
 Pheny t
oi n  I nsul in
 Smoki ng  NTG
 Phenobar bital  Ot her s: cabazi taxel ,car must i
ne,
 Oxcar bazepi ne( and docet axel , etoposi de, ixabepi lone,
esl icar bazepi ne) pacl itaxel ,suf entani l
, temsi r olimus,
 Ri fampi n( andr ifabut i
n, rifapent ine) teni posi de, t
hi opent al
 Car bamazepi ne( al soanaut o- 
inducer )
 St .John’ sWor t





1

, Keydr
ugs-SALINE( nodext rose) Keydrugs-TERATOGENS
o ACI DAPE o Acne: isot ret i
noi n, topi cal retinoi ds( i
ncluding
 Ampi cill
in tazar otene)
 Caspof ungi n o Abx: qui nol ones, tetracy clines
 I nf liximab o Ant icoagul ant s: war farin
 Dapt omy ci n o HLD, HF, HTN: st atins, RAASi nhi bitors( ACEi
,
 Ampi cill
in/ sul bact am ARBs, al i
ski ren, sacubi tril
/ val
sar t
an)
 Pheny toin o Hor mones: most ,incl udingest radiol,
 Er tapenem pr ogest er one[ megest erol (Megace) ]
,
 Ot her s: abat acept ,azaci tidine, raloxi fene, Duav ee, test ost erone,
bel i
mumab, bev aci zumab, cont racept ives
i
dar uci zumab, ironsucr ose, sodi um o Mi gr aine: dihy droer got ami ne, ergotami ne
ferricgl uconat ecompl ex , o Ot heri mpor tantt er atogens: hy droxy urea,
nat alizumab, t
rast uzumab l
ithi um, MTX, mi sopr ost ol,par oxet i
ne,
 Keydr
ugs-DEXTROSE( nosal ine) ribav irin, thal idomi de, topi ramat e,VPA,
o ABS div alproex, wei ghtl ossdr ugs
 Amphot er icinB  Avoi
di nPEDI ATRI CS
 Bact rim o Cont raindi cat ed
 Sy ner ci d( qui nupr istin/dal fopr isti
n)  Codei neage<12y
 Ot her s: car f i
lzomi b,MMF,  Tr amadol age<12y
pent ami di ne  Pr omet hazi neage<2y
 Keydr
ugs-commondr ugswi t
hFI LTERr equi rement s  Cef tr iaxonei nneonat es1- 28d
o Most :0.22- mi cr onf il
terdur ing o Notgener allyr ecommended
administr
at ion*  Qui nol ones
o Pushyguy sinLALAl and  Tet racy clinesage<8y
 Pheny toin  OTCcoughandcol dpr epar ationsin
 Gol imumab age<6y
 Li pids-1. 2mi cr on*  Li
vev accines
 Amphot er icinB( l
ipidf or mul ations) * o I nject ions
 Lor azepam  MMR
 Ami odar one  MMRV
 *l argerpor esi zef il
ter  Var icel la
r equi red; amphopr epar e  Zost er
usi nga5- mi cronf ilter  Yel lowf ev er
 Ot her s: abat acept ,abci ximab, o Ot herr out es
digoxi ni mmunef ab, infliximab,  I nf l
uenzai nt ranasal
i
sav uconazoni um, manni tol,  Rot av ir
us
thiot epa  Chol er a
 Keydr
ugs-DONOTREFRI GERATE  Ty phoi d
o Dearsweetphar maci st, mar rymef or ev er,  Vacci
nesf orspeci f i
ccondi tions
eter
nally o Pr egnancy
 Dexmedet omi dine  I nf l
uenzav acci ne
 SMX- TMP  Tdapx1wi t heachpr egnancy
 Pheny toin (opt imal timebet weenweeks27
 Met roni dazol e and36)
 Moxi floxaci n  Li v ev acci nesCIdur ingpr egnancy
 Fur osemi de o Aspl eni a
 Enoxapar in  H.i nf luenzaet ypeB( HI B)
 Ot her s: acet ami nophen, acycl ov i
r,  Pneumococcal (Prev narand
def er oxami ne( Desf eral) , Pneumov ax23)
l
ev et iracet am, pent ami di ne,  Meni ngococcal
valpr oat e  Sel
ecteddr ugst hatCAUSEKI DNEYDI SEASE
 Keydr
ugs-PROTECTFROM LI GHTDURI NG o Ami nogl ycosi des
ADMINI
STRATION o Amphot er icinB
o Del i
verev eryneededmedi cationpr ot ect ed o Ci splat in
 Doxy cy cline o Col ist i
met hat e
 Epopr ost enol o CYA
 Ni t
r opr ussi de o Loopdi uret ics
 Mi caf ungi n o NSAI Ds
 Phy tonadi one o Radi ogr aphi ccont rastdy e
 Ot her s: ant hr acy clines, dacar bazi ne, o Tacr olimus
pent ami di ne o Vancomy ci n
 

2

, Studytip:CrCl vsGFR Selectdrugst hatar eCII NKI DNEYI MPAI RMENT
o Cr Cl o Cr Cl <60
 Cockcr oft-Gaul tequat ion  Ni trof ur ant oin
140- pat i
enta g e o Cr Cl <50
 Cr Cl= ×we ightinkg
72xS Cr  El vitegr av ir/cobi cistat/
(×0.85i ff ema l
e ) emt ri
ci tabi ne/ TDF( Stribild)
 ForCr Cl cal culation, useABW i f  Vor iconazol eI V
pat i
enti s<I BW, useI BW isnor mal o Cr Cl <30
wei ght( byBMI )  Av anaf il
 Dosi ngadj ust ment sandCI ’
sar e  Bi sphosphonat es
gener allybasedonCr Cl calculated  Dabi gat ran
withCockcr oft-Gaul t  Dul oxet i
ne
o GFR  El vitegr av ir/cobi cistat/
 CKD- EPIorMDRDequat i
on emt ri
ci tabi ne/ TAF( Genv oy a)
 Usedf orst agingki dneydi sease  Fondapar inux
andf ordosi ngsel ectdr ugs  NSAI Ds
 Notcommonl ycal culat edint he  Pot assi um spar i
ngdi uretics
cli
ni cal setting, butmayber eported  Ri var oxaban
bysomel abor atories  Tadal af i
l
 Fort heexam, i
fGFRi snotpr ovided,  Tr amadol ER
CrCl pr ov i
desacl oseest i
mat ef or o GFR<30
doingandCIpur poses  Genv oy a
 Selectdrugst hatrequi r e OR I NTERVALWI TH  SGLT2i nhi bitors( canagl i
f l
ozin,
I
MPAI REDKI DNEYFUNCTI ON dapagl iflozi n,empagl if
lozi n)
o Ant i-i
nfectives  Met f ormi n
 Ami nogl ycosi des( dosi ngi nterval
, o Ot her s
primar ily)  Dof et il
ide
 Azt reonam  Edoxaban
 Bet a-lact ams  Gl ybur ide
 Pol ymy xins  Meper idine
 Qui nol ones( exceptmoxi f
loxacin)  Sot alol
 SMX- TMP  Keydr ugsthat KLEVELS
 Vancomy cin o ACEi
 Ant i-tuber cul osi smedi cations o ARBs
 Ant iviral s o Al dost eroner ecept orant agonists( ARAs)
 Amphot erici nB o Canagl iflozin
 Fl uconazol e o Dr ospi renone- cont ainingCOCs( combi ned)
 NRTI s, includi ngt enof ovir o Kcont ainingI VF( includi ngTPNs)
o CV o Ksuppl ement s
 Ant iar r
hy thmi cs( digoxi n, o SMX- TMP
disopy rami de, dof etil
ide, o Tacr ol i
mus
procai nami de, sot alol) o Ot her s:al i
ski ren, CYA, ev er
olimus,
 Dabi gat ran glycopy rrolat e, hepar in( chronicuse) ,NSAIDs,
 LMWHs pentami dine
 Ri var oxaban  Directacti
ngant ivir
als: pref er r
edHCVr egimens
 St at ins i
ncl ude2-3DAAswi thdi fferentMOAs( ofteni n1
o Pai n/gout tablet)
 Al lopur inol
Mechani
sm Namecl
ue
Exampl es
 Col chi cine
Grazopr evi
r
 Gabapent in, pregabal in -
prevai
r
NS3/4Apr otease Paritaprevi
r
 Mor phi neandcodei ne
i
nhibi
tors Simepr evir
 Tr amadol ER PforPI
Voxilaprevir
o GI
Daclatasv i
r
 Famot idine, r
ani ti
dine
-
asvir Ledipasv i
r
 Met ocl opr ami de NS5Ar epl
icati
on
Ombi t
asvir
o Ot her s complexinhibit
ors
Af
orNS5A Pibrentasvir
 Bi sphosphonat es
Velpatasv i
r
 CYA
 Li thium -buvir
NS5Bpol ymerase Dasabuv i
r
 Topi r amat e i
nhibi
tor Sofosbuv ir
Bf
orNS5B





3